Announcing the launch of Breakthroughs Today, Cures Tomorrow, our 20th anniversary campaign!
The NETRF Board of Directors is pleased to announce that Josh Mailman has joined the Board. Josh is an internationally-recognized advocate for Neuroendocrine tumor patients
Dr. Guillermina Lozano, Ph.D. of MD Anderson Cancer Center has worked tirelessly to understand how pancreatic neuroendocrine tumors develop so that we might use that
Dr. Christopher Heaphy of Johns Hopkins University has been selected as the first Basic Translational Science Investigator, through a collaboration between NETRF and The North
The NET Research Foundation is delighted to welcome Dr. Chrissie Thirlwell, Senior Lecturer and Consultant in Medical Oncology at the Royal Free Hospital NET Unit
Funding to find cure for rare cancer affecting over 170,000 Americans The Neuroendocrine Tumor (NET) Research Foundation today announced that it has received a major
CAR T (Chimeric Antigen Receptor T-cell) therapy, an immunotherapy that harnesses the body’s own T cells to kill cancer cells, showed success in treating blood